Hostname: page-component-84b7d79bbc-4hvwz Total loading time: 0 Render date: 2024-07-26T03:12:31.387Z Has data issue: false hasContentIssue false
  • English
  • Français

Likelihood of persistent carriage of carbapenem-resistant Acinetobacter baumannii on readmission in previously identified carriers

Published online by Cambridge University Press:  05 August 2019

Amir Nutman Open the ORCID record for Amir Nutman [Opens in a new window] ,
Anat Lerner ,
Noga Fallach ,
David Schwartz  and
Yehuda Carmeli
Amir Nutman*
Affiliation:
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel National Center for Infection Control and Antibiotic Resistance, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Anat Lerner
Affiliation:
National Center for Infection Control and Antibiotic Resistance, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Noga Fallach
Affiliation:
National Center for Infection Control and Antibiotic Resistance, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
David Schwartz
Affiliation:
National Center for Infection Control and Antibiotic Resistance, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Yehuda Carmeli
Affiliation:
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel National Center for Infection Control and Antibiotic Resistance, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
*
Author for correspondence: Amir Nutman, E-mail: amirn@tlvmc.gov.il
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with carbapenem-resistant Acinetobacter baumannii-positive clinical cultures during a prior hospitalization were screened using high sensitivity methods upon first readmission. Of 38 patients, 31.6% screened positive; 42% screened positive within 2 months from discharge, and 14% screened positive more than 5 months from discharge. Carriage was persistent up to 285 days.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 40 , Issue 10 , October 2019 , pp. 1188 - 1190
Copyright
© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Peleg, AY, Seifert, H, Paterson, DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–582.CrossRefGoogle ScholarPubMed
Lemos, EV., de la Hoz, FP, Alvis, N, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect 2014;20:174–180.CrossRefGoogle ScholarPubMed
Word Health Organization. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities, vol 91. Geneva: WHO; 2017.Google Scholar
Tomczyk, S, Zanichelli, V, Grayson, ML, et al. Control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. Clin Infect Dis 2019;68:873–884.CrossRefGoogle ScholarPubMed
Marchaim, D, Navon-Venezia, S, Schwartz, D, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii . J Clin Microbiol 2007;45:1551–1555.CrossRefGoogle ScholarPubMed
Nutman, A, Lerner, A, Schwartz, D, Carmeli, Y. Evaluation of carriage and environmental contamination by carbapenem-resistant Acinetobacter baumannii . Clin Microbiol Infect 2016;22:949.e5–949.e7.CrossRefGoogle ScholarPubMed
Burnham, JP, Kwon, JH, Olsen, MA, Babcock, HM, Kollef, MH. Readmissions with multidrug-resistant infection in patients with prior multidrug resistant infection. Infect Control Hosp Epidemiol 2018;39:12–19.CrossRefGoogle ScholarPubMed